Spectral Molecular Imaging, Inc. Reaffirms Commitment to Early Detection of Melanoma by Hyperspectral Imaging

Published: Nov 19, 2010

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Cascade Technologies, Corp. (OTCBB: CSDT) announced today that, in response to significant recent attention to the Food and Drug Administration (FDA) panel evaluation of Mela Sciences’ (Nasdaq: MELA) MelaFindTM device, the company has received a number of inquiries about its similar instrument. "We believe," said Dr. Daniel Farkas, Chairman and CEO, "that it is useful to reaffirm our position on the non-invasive detection of melanoma by our SkinSpectTM device under development."

Back to news